U.S. FDA Approves MedMira’s Advanced Reveal® G4 Rapid HIV-1/2 Antibody Test

Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR). MedMira Inc. proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States. This achievement marks a significant milestone for MedMira, positioning the company as a key player […]